Company profile: Checkpoint Therapeutics
1.1 - Company Overview
Company description
- Provider of immuno-oncology and targeted oncology therapies in development, advancing a pipeline including cosibelimab (fully human anti-PD-L1 monoclonal antibody), olafertinib (oral third-generation irreversible EGFR inhibitor for NSCLC), CK-103 (BET bromodomain inhibitor), CK-302 (agonistic GITR antibody), and an anti-CAIX antibody for renal cell carcinoma, plus product purchases, in-licensing and co-development.
Products and services
- Cosibelimab: Clinical-stage PD-L1 monoclonal antibody restoring cytotoxic T-cell activity against tumor cells, under evaluation for metastatic cutaneous squamous cell carcinoma treatment
- CK-302: Fully-human agonistic antibody engaging GITR to activate immune effector cells and potentially drive tumor regression across solid tumor oncology indications
- Olafertinib: Third-generation, oral irreversible EGFR kinase inhibitor for NSCLC that improves tolerability and safety by minimizing inhibition of wild-type EGFR
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Checkpoint Therapeutics
Applied Proteomics
HQ: United States
Website
- Description: Provider of protein biomarker discovery solutions, including SimpliPro Colon Test—a blood test for healthcare providers to aid colorectal health assessment by measuring 11 protein markers associated with colorectal cancer and advanced adenoma—plus a mass-spectrometry (tandem LCMS) proteomics platform, proprietary workflow management system, and advanced visualization tools.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Applied Proteomics company profile →
Endomag
HQ: United Kingdom
Website
- Description: Provider of magnetic sensing technologies for breast cancer care, including the Sentimag surgical guidance system to detect tumors and lymph nodes, Magseed markers for precise tissue and lymph node localization, Magtrace lymphatic tracer for sentinel node biopsy with clear signal and visual guidance, and Magseed Pro self-expanding seed for precise deployment and anchoring.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Endomag company profile →
Vaxess
HQ: United States
Website
- Description: Provider of needle-free vaccine and therapeutic delivery solutions, offering the MIMIX applicator with patch for skin-based administration and silk fibroin biomaterials that create stable, biocompatible delivery systems, with a focus on improving access to vaccines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vaxess company profile →
PharmaMar
HQ: Spain
Website
- Description: Provider of oncology medicines inspired by the sea, discovering antitumor molecules from marine organisms through integrated research and development. Delivers innovative products to equip healthcare professionals with new tools to treat cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PharmaMar company profile →
Galvanize Therapeutics
HQ: United States
Website
- Description: Provider of a biomedical platform delivering therapeutic products and services, including Aliya™ PEF System, a pulsed electric field technology for soft tissue ablation in various medical applications such as oncology, and RheOx®, a device targeting chronic bronchitis symptoms by reducing mucus-producing airway cells through pulsed electric fields.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Galvanize Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Checkpoint Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Checkpoint Therapeutics
2.2 - Growth funds investing in similar companies to Checkpoint Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Checkpoint Therapeutics
4.2 - Public trading comparable groups for Checkpoint Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →